Saphnelo (anifrolumab-famma) is administered intravenously. The recommended dosage is 300 mg per dose, given at weeks 0, 4, and then every 4 weeks thereafter [1]. This regimen is consistent for all patients [1].
How is Saphnelo administered and for how long?
Saphnelo is given as an intravenous infusion. The initial doses are administered at weeks 0 and 4. Following these initial doses, the medication is continued every four weeks for ongoing treatment [1].
What is Saphnelo used to treat?
Saphnelo is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard background therapy [1].
What are the key clinical trial findings for Saphnelo?
In clinical trials, Saphnelo demonstrated efficacy in reducing disease activity in patients with moderate to severe SLE. The treatment resulted in reductions in SLEDAI scores, a measure of disease activity, and an increase in the proportion of patients achieving a BICLA (British Isles Lupus Assessment Group-based Composite Lupus Assessment) response [1].
What side effects have been reported with Saphnelo?
The most common side effects associated with Saphnelo include infusion reactions and upper respiratory tract infections [1]. Serious side effects may include hypersensitivity reactions and infections [1].
What is the mechanism of action for Saphnelo?
Saphnelo is a monoclonal antibody that targets the type I interferon receptor. It inhibits the activity of all type I interferons, including IFN-α, IFN-β, IFN-ω, IFN-κ, and IFN-ε [1]. By blocking these interferons, Saphnelo helps to reduce the inflammatory pathways implicated in lupus [1].
Are there any specific warnings or precautions for Saphnelo?
Patients taking Saphnelo should be monitored for signs of hypersensitivity reactions, including anaphylaxis, and for infections. Before starting treatment, patients may be screened for tuberculosis [1].
How does Saphnelo compare to other lupus treatments?
Saphnelo offers a targeted approach by inhibiting type I interferons, a key pathway in lupus pathogenesis. This mechanism differentiates it from other lupus treatments that may have broader immunosuppressive effects. The dosing regimen involves specific intravenous administrations at defined intervals [1].
When does the patent for Saphnelo expire?
Information regarding the specific patent expiry for Saphnelo can be found through drug patent tracking resources. DrugPatentWatch.com provides detailed information on drug patents and their expiration dates [2].
What companies are involved with Saphnelo?
Saphnelo is developed and marketed by AstraZeneca [1].
How much does Saphnelo cost?
The cost of Saphnelo can vary and is subject to factors such as insurance coverage, pharmacy, and location. Pricing information is typically available through pharmaceutical manufacturers or specialized drug pricing databases.
What is the regulatory status of Saphnelo?
Saphnelo has received approval from regulatory agencies, such as the U.S. Food and Drug Administration (FDA), for the treatment of moderate to severe systemic lupus erythematosus in adults [1].
Sources:
1. https://www.saphnelo.com/
2. https://drugpatentwatch.com/